What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association

BMC Clinical Pharmacology

Volumn 11, Issue , 2011, Pages

  Vilhelmsson, Andreas ^a   Svensson, Tommy ^b   Meeuwisse, Anna ^c   Carlsten, Anders ^d  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ADRENERGIC RECEPTOR BLOCKING AGENT;

ADOLESCENT; AGED; AGGRESSIVENESS; ANXIETY; ARTICLE; CONSUMER ADVOCACY; CONSUMER HEALTH INFORMATION; DEPRESSION; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PHARMACEUTICAL CARE; PRODUCT SAFETY; SELF REPORT; SENSORY DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; SWEDEN; WITHDRAWAL SYNDROME; ADULT; AGE; CONSUMER; DRUG SURVEILLANCE PROGRAM; HOSPITALIZATION; INTERNET; MIDDLE AGED; PSYCHOLOGICAL ASPECT; SEXUAL DEVELOPMENT; TOXICITY AND INTOXICATION;

ADOLESCENT; ADRENERGIC ANTAGONISTS; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CONSUMER ORGANIZATIONS; CONSUMER PARTICIPATION; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PHARMACOVIGILANCE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; SUBSTANCE WITHDRAWAL SYNDROME; SWEDEN; YOUNG ADULT;

EID: 80054869842     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-11-16     Document Type: Article

References (39)

1. Nordic Medico-Statistical Committee (NOMESCO) Medicines Consumption in the Nordic Countries 2004-2008 2010, Copenhagen, Nordic Medico-Statistical Committee (NOMESCO).
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279:1200-1205. 10.1001/jama.279.15.1200, 9555760.
3. Classen DC, Pestonik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997, 277(4):301-306. 10.1001/jama.277.4.301, 9002492.
4. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL. The costs of adverse drug events in hospitalized patients. JAMA 1997, 277(4):307-311. 10.1001/jama.277.4.307, 9002493.
5. World Health Organization (WHO) The importance of pharmacovigilance: an essential tool 2002, Geneva, World Health Organization (WHO).
6. World Health Organization (WHO) Safety of medicines-a guide to detecting and reporting of adverse drug reactions. Why health professionals need to take action 2002, Geneva, World Health Organization (WHO).
7. Pharmacovigilance - Major developments. , http://ec.europa.eu/health/human-use/pharmacovigilance/developments/index_en.htm#
8. Regulation (EU) No 1235/2010 of the European Parliament and of the Council. Official Journal of the European Union L 348/1., http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF
9. Waller P. Getting to grips with the new European Union pharmacovigilance legislation. Pharmacoepidemiology and drug safety 2011, 20:544-549. 10.1002/pds.2119, 21394813.
10. Herxheimer A, Crombag MR, Alves TL. Direct patient reporting of adverse drug reactions. A twelve-country survey & literature review 2010, Health Action International (HAI) (Europe). Amsterdam.
11. Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to?. Drug Saf 2011, 34(3):187-197. 10.2165/11586620-000000000-00000, 21332243.
12. World Health Organization (WHO) The safety of medicines in public health programmes: Pharmacovigilance an essential tool 2006, Geneva, World Health Organization (WHO).
13. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions. A retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009, 32(11):1067-1074. 10.2165/11316680-000000000-00000, 19810778.
14. van Geffen ECG, van der Wal SW, van Hulten R, de Groot MCH, Egberts ACG, Heerdink ER. Evaluation of patients' experiences with antidepressants reported by means of a medicine reporting system. Eur J Clin Pharmacol 2007, 63:1193-1199. 10.1007/s00228-007-0375-4, 2071966, 17874086.
15. van Grootheest K, van Puijenbroek EP, de Jong-van den Berg LTW. Do pharmacists' reports of adverse drug reactions reflect patients' concerns?. Pharm World Sci 2004, 26:155-159.
16. Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependency and suicidal behaviour with paroxetine. Int J Risk & Safety in Medicine 2003, 16:5-19.
17. Herxheimer A, Mintzes B. Antidepressants and adverse effects in young patients: uncovering the evidence. CMAJ 2004, 170(4):487-489. 332715, 14970096.
18. Nordic Medico-Statistical Committee (NOMESCO) Health Statistics in the Nordic Countries 2006 2008, Copenhagen, Nordic Medico-Statistical Committee (NOMESCO).
19. The National Board of health and Welfare Official statistics of Sweden. Statistics-Health and Medical Care. Pharmaceuticals-statistics for 2010 2011, Stockholm, The National Board of health and Welfare.
20. The National Board of health and Welfare Official statistics of Sweden. Statistics-Health and Medical Care. Pharmaceuticals-statistics for 2009 2010, Stockholm, The National Board of health and Welfare.
21. Mjörndal T, Danell Boman M, Hägg S, Bäckström M, Wiholm BE, Wahlin A, Dahlqvist R. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002, 11:65-72. 10.1002/pds.667, 11998554.
22. Jönsson AK, Hakkarainen KM, Spigset O, Druid H, Hiselius A, Hägg S. Preventable drug related mortality in a Swedish population. Pharmacoepidemiol Drug Saf 2010, 19(2):211-215. 10.1002/pds.1890, 19998370.
23. Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008, 65(4):573-579. 10.1111/j.1365-2125.2007.03064.x, 2291376, 18070216.
24. Bäckström M, Mjörndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 2004, 13:483-487. 10.1002/pds.962, 15269932.
25. WHO Classification The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD) [Online] 2010. [Citat: den 8 May 2010.], WHO Classification., http://www.who.int/classifications/atcddd/en/
26. MedDRA. (last accessed 16 August 2001 [password required].., http://www.meddramsso.com
27. Läkemedelsföreningen, LIF (The Swedish Association of the Pharmaceutical Industry). Farmacevtiska specialiteter i Sverige 2004 (FASS 2004) (Pharmaceutical Specialties in Sweden-Swedish Physicians Desk Reference) 2004, Stockholm, Elanders.
28. Läkemedelsföreningen, LIF (The Swedish Association of the Pharmaceutical Industry). FASS.se för förskrivare (FASS.se for prescribers) , http://www.fass.se
29. Egberts TCG, Smulders M, de Koning FHP, Meyboom RHB, Leufkens HGM. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996, 313:530-531. 2351951, 8789980.
30. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2006, 63(2):148-156.
31. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008, 22(3):330-332. 10.1177/0269881107081550, 18515448.
32. Passier A, ten Napel M, van Grootheest K, van Puijenbroek E. Reporting of adverse drug reactions by general practioners. A questionnaire-based study in the Netherlands. Drug Saf 2009, 32(10):851-858. 10.2165/11314490-000000000-00000, 19722728.
33. World Health Organization (WHO) The importance of pharmacovigilance: safety monitoring of medicinal products 2002, Geneva, World Health Organization (WHO).
34. Aagaard L, Hansen EH. Consumers' reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol 2010, 69(3):317-318. 10.1111/j.1365-2125.2009.03584.x, 2829705, 20233206.
35. Nordic Medico-Statistical Committee (NOMESCO) Medicines Consumption in the Nordic Countries 1999-2003 2004, Copenhagen, Nordic Medico-Statistical Committee (NOMESCO).
36. Zopf Y, Rabe C, Neubert A, Gaßmann KG, Rascher W, Hahn EG, Brune K, Dormann H. Women encounter ADRs more often than do men. Eur J Clin Pharmacol 2008, 64:999-1004. 10.1007/s00228-008-0494-6, 18604529.
37. Breslau N, Schultz L, Peterson E. Sex differences in depression: a role for preexisting anxiety. Psychiatry Research 1995, 58:1-12. 10.1016/0165-1781(95)02765-O, 8539307.
38. Meijer WEE, Heerdink ER, Leufkens HGM, Herings RMC, Egberts ACG, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004, 60:57-61. 10.1007/s00228-004-0726-3, 14985889.
39. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clinical Pharmacology 2010, 10(16).